The reverse stock split is intended to enable Adicet to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf†gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patie ...

融资活动 - 公司以注册直接发行的方式定价7000万1000股普通股 [1] - 公司同时向部分投资者发行可购买1000万股普通股的预先资助权证以代替普通股 [1] 公司业务 - 公司是一家临床阶段生物技术公司 [1] - 公司专注于发现和开发用于治疗自身免疫性疾病和癌症的同种异体γδ T细胞疗法 [1]